Despite Reliable Cash Flow, Osmetech Divests Blood Gas Biz to Chase Array-Based Dx Market

Although its molecular diagnostics unit has yet to demonstrate its viability, Osmetech is convinced that diagnostics will bear more long-term fruit than the blood gas analysis business was capable of providing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.